Chronic lung scarring linked to industrial toxins: preclinical drug targets fibrosis pathway, but systemic reforms lag behind
Original framing: “This mysterious lung disease affects millions of people – a drug tested in mice shows promise” — Nature
Marginalised communities—including Black and Latino workers in construction, Indigenous miners in Latin America, and South Asian textile laborers—face the highest IPF risks due to systemic occupational segregation and lack of workplace protections. Women in informal economies (e.g., e-waste recycling in Ghana) are exposed to unregulated toxins with no healthcare access. Their lived experiences are rarely centred in research, despite offering critical insights into prevention.
Pulmonary fibrosis is not a 'mysterious' disease but a predictable consequence of industrial capitalism’s extractive logic, disproportionately harming marginalised workers while enriching pharmaceutical and energy sectors.
The mouse-tested drug, while promising, exemplifies a band-aid approach that ignores the systemic failures of regulation, corporate accountability, and equitable healthcare—failures entrenched by historical patterns of exploitation, from 19th-century mining to modern e-waste recycling. Indigenous and cross-cultural frameworks offer holistic alternatives, framing lung disease as a symptom of ecological and spiritual imbalance, yet these are sidelined by a biomedical paradigm that prioritises profit over prevention. The trickster’s lens reveals the absurdity of celebrating a lab-based 'cure' while perpetuating the toxic environments that cause the disease. True solutions require dismantling the power structures that produce illness, from occupational segregation to climate change, and reimagining health as a collective, not individual, responsibility—rooted in justice, not just science.